Medical Oncology

University of Chicago

Questions discussed in this category

How do you approach patients with AL amyloidosis with t(11;14) who have not achieved a hematologic complete response to induction therapy with 6 cycles of Dara-CyBorD?

Specifically, in the setting of patients that have had a PR or VGPR and are not actively progressing.

1 Answer available

How would you approach BCMA-directed therapy in a patient with myeloma and renal failure on dialysis?

Would you prefer CAR-T or bi-specific or neither? If CAR-T, how do you approach lymphodepletion?

2 Answers available

Do you always start treatment for patients who meet diagnostic criteria for multiple myeloma by SLiM criteria alone?

i.e., 60+% bone marrow plasmacytosis, light chain ratio >100, and/or >1 MRI lesion

2 Answers available

What is your preferred approach to a patient with myeloma who has refractory disease to Dara-VRd in the frontline setting?

2 Answers available

Assuming all options for BCMA-directed therapy are available, how would you approach treatment for a patient with 4 prior lines of myeloma-directed therapy who is eligible for a BCMA-directed therapy?

Ide-cel? Cilta-cel? Teclistamab?

1 Answer available

For relapsed/refractory myeloma, how long of a disease-free interval from first autologous transplant do you recommend before considering a second autologous transplant?

1 Answer available

How would one alter therapy in a transplant-ineligible AL amyloidosis with less than a complete response to six cycles of Dara-CyBorD?

Would you continue with daratumumab maintenance per ANDROMEDA or switch regimen?

2 Answers available

How do you approach a patient with an anaplastic plasmacytoma without systemic evidence of disease in the bone marrow?

What about multiple anaplastic plasmacytoma without bone marrow involvement?

2 Answers available

Do you continue bortezomib past 8 cycles for transplant ineligible patients with multiple myeloma on VRd who are tolerating therapy well with no neuropathy?

Would you use MRD status to guide your decision making?

1 Answer available

Papers discussed in this category

The Lancet. Oncology, 2019-01

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

J Clin Oncol, 2020 Oct 06

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.

Journal of clinical pathology, 2017-09

Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma.

Leukemia, 2018-06

Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset.

Blood Cancer J, 2021 Jan 11

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.

N Engl J Med,

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

Lancet Haematol,

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.

Leukemia, 2020 Jul 21

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.

N Engl J Med, 2022 Jun 05

Teclistamab in Relapsed or Refractory Multiple Myeloma.

N Engl J Med,

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

J Clin Oncol, 2022 Jun 04

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.

J Clin Oncol, 2022 Oct 21

Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).

Leukemia, 2022 Apr 11

Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.

Blood Cancer J, 2022 Sep 02

Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma.

Cancer, 2021 Jun 28

Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.

N Engl J Med, 2023 Feb 10

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

Experimental hematology & oncology, 2022 Feb 28

Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis.

American journal of hematology, 2022 Jul 05

Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study.

Blood advances, 2023 Oct 24

Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis.

Blood, 2018 Aug 14

Treatment of AL amyloidosis with bendamustine: a study of 122 patients.

Medical Oncology

University of Chicago

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology